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Abstract. The incidence of post-transplant diabetes
mellitus was evaluated retrospectively in 901 consecutive
renal transplant recipients. Thirty-two (3.6%) patients
developed diabetes mellitus requiring drug therapy. 18 of
32 became hyperglycaemic within 3 months of transplan-
tation. Post-transplant diabetes mellitus occurred in 24 of
628 (3.8%) patients treated with conventional therapy
consisting in azathioprine and prednisone, and in 8 of 273
(2.9%) patients receiving cyclosporin A (CsA) in addition
(triple therapy). To identify predisposing factors 32 non-
diabetic patients matched for age, sex, number of graft,
immunosuppressive protocol, and graft function at onset
of diabetes were used as case controls. Thirteen of 32
patients with diabetes mellitus and 5 of 32 control
patients had abnormal glucose tolerance pretransplant
(P< 0.025). HLA-B8 was significantly more frequent in
patients with post-transplant diabetes mellitus than in
control patients (9 of 29 vs 2 of 31, P<0.02). Twelve
(38%) patients became diabetic during or immediately
after anti-rejection therapy with intravenous pulse
prednisone. Four diabetic patients experienced chronic
pancreatitis pre-transplant. Family history of diabetes
mellitus, bodyweight, number of rejection episodes, and
immunosuppressive drug doses were similar in both
groups. Actuarial patient and graft survival was not
significantly different in diabetic patients and controls,
although 10-year data tended to be better in controls.
Thus, post-transplant diabetes mellitus was not a fre-
quent complication in patients sometimes predisposed by
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an impaired glucose tolerance pre-transplant and was
triggered by pulse prednisone therapy in 38%.
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Introduction
Persistent hyperglycaemia has been repeatedly observed
in renal allograft recipients and is believed to be induced by
immunosuppressive therapy. In 1964 Starzl [1] described
the appearance of 'steroid diabetes' in previously non-
diabetic renal transplant recipients. This was confirmed
by several other groups [2-6]. Some authors observed
post-transplant diabetes mellitus in association with
antilymphocyte globulin [7] or antithymocyte globulin
therapy [8]. Depending on the criteria of definition for
hyperglycaemia, the incidence of post-transplant diabetes
mellitus varied from 3% to 46% in these studies. Recently
a greater frequency has been reported in renal allograft
recipients receiving azathioprine and CsA compared to
conventional protocols with azathioprine and prednisone
[9-11]. The pathogenesis is not completely understood
and diabetogenic risk factors other than immunosuppres-
sion were not clearly identified. The aim of this study was
to determine the frequency of post-transplant diabetes
mellitus requiring drug therapy in a large population of
kidney transplant recipients treated with triple therapy
and conventional therapy. To evaluate predisposing and
triggering factors patients developing post-transplant
diabetes mellitus were compared to matched controls.
Post-Transplant Diabetes Mellitus
Patients and Methods
Patients
We retrospectively reviewed the course of 1149 consecu-
tive cadaveric renal transplants performed in 986 patients
at the University Hospital of Zurich between December
1964 and August 1988. Of the recipients, 901 were not
diabetic prior to transplantation. Post-transplant diabetes
mellitus was denned as follows: (1) two consecutive fasting
blood glucose values > 6.7 mmol/1, and (2) adminis-
tration of insulin or oral hypoglycaemic drugs. According
to these criteria 32 patients were included in the study
group. Thirty-two non-diabetic recipients matched for
age (+ 5 years), sex, immunosuppressive therapy, number
of transplant, and graft function were selected as case
controls to determine risk factors and survival rates. The
time of transplantation was as similar as possible com-
pared to the study "group (±3 years). Each control was
analysed at the time when the matched patient mani-
fested diabetes mellitus and graft function was considered
equal if serum creatinine values were in the same range
according to the following classification: < 130, 130-260,
260-400, >400umol/l. The clinical course of diabetic
patients and controls was followed until August 1988
unless the patient died earlier.
The cadaveric allografts in both groups were selected
on the basis of HLA typing and a negative cross-match
between donor lymphocytes and recipients' sera. Three
diabetic patients and one control were transplanted
before 1969 without HLA typing results. The number of
HLA-A and B antigen mismatches averaged 0.55 + 0.63
(SD) and 1.10 + 0.62 in the study group compared to
0.87 + 0.62 and 1.17±0.75 in controls. Since 1979,
HLA-DR typing has been performed additionally in 15
diabetic patients and 20 controls (mean number of DR
mismatches 0.53 + 0.64 and 0.65 ± 0.59, respectively). The
number of HLA antigens described to be associated
positively (HLA-B8, B15, DR3, DR4) or negatively
(HLA-B7, DR2) with insulin-dependent diabetes mellitus
[12,13] was calculated in both groups.
Immunosuppression
Since 1984, 273 recipients received triple therapy. CsA
was given preoperatively, and on the first 3 postoperative
days 3 mg/kg per day intravenously. The oral medication
was started on the 4th day with 5 mg/kg per day. The
dosage was adjusted to maintain a 24-h trough level of
300-500 ng/ml during the first 3 months and of 200-
400 ng/ml in the following, as measured by whole blood
fluorescence polarisation immunoassay (Abbott, North
Chicago, USA). Azathioprine was given postoperatively
in an oral dose of 1 mg/kg per day. Oral prednisone was
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administered at a dose of 1 mg/kg per day followed by
40 mg/day from the 3rd week post-transplant. Thereafter,
the dose was continuously reduced by lOmg monthly
to a maintenance dose of 10 mg/day. The cumulative
prednisone dose after 1 year was 5.7 g. Six hundred and
twenty-eight patients were treated with conventional
therapy (1964-1984) consisting of azathioprine 3 mg/kg
per day plus prednisone as described above.
Rejection Episodes
Rejection episodes were treated with steroid pulses
(methylprednisolone 1 g/day i.v. for 3-5 days) or, if pred-
nisone-resistant, with antithymocyte globulin (3 mg/kg
per day) or OKT3 (5 mg/day) for 7-14 days. The diag-
nosis of rejection episodes was based upon clinical criteria
(fever, graft swelling, tenderness, oliguria), a significant
increase in serum creatinine (20% or more), normal or
subtherapeutic CsA blood values, and characteristic graft
biopsy in the case of episodes resistant to steroid pulses.
Oral Glucose Tolerance Test
An oral glucose tolerance test (GTT) prior to trans-
plantation was performed in 21 of 32 patients with post-
transplant diabetes mellitus and in 23 of 32 controls. The
remaining recipients were analysed on the basis of their
fasting serum blood glucose values, except for one
diabetic and one control of whom the pretransplant
blood glucose values were not known. The GTT results
were subdivided as follows: (1) diabetic type with fasting
blood glucose > 6.7 mmol/1 and/or 2-h blood glucose
> 10 mmol/1; (2) normal type with fasting blood glucose
< 5.8 mmol/1 and/or 1-h blood glucose < 10.0 mmol and
2-h blood glucose <6.7 mmol/1; and (3) impaired glucose
tolerance with fasting blood glucose between 5.8 and
6.7 mmol/1 and/or 1-h blood glucose > 10.0 mmol/1 and
2-h blood glucose between 6.7 and 10.0 mmol/1.
Data Analysis
Various clinical and laboratory parameters were tabulated
and compared in control and study recipients. Student's t
test and Fisher's exact test were employed to test signifi-
cance of results. Cumulative actuarial patient and graft
survival was calculated by the life table method [14].
Results
Table 1 shows the matching criteria of diabetic patients
and controls. One diabetic could not be matched for sex
and another diabetic with a third graft was matched with a
first-graft recipient. Twenty-seven diabetic patients and
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28 controls were first-graft recipients. In each group
conventional therapy was administered to 24 and triple
therapy to eight patients. Post-transplant diabetes mel-
litus occurred in 32 (3.6%) of 901 kidney transplant
recipients and was not more frequent in patients receiving
triple therapy compared to conventional therapy (Table
2). Twenty (63%) diabetic patients required insulin
therapy with a mean dose of 35.6+ 13.3 units per day at
the onset of diabetes. Only three of these 20 were less than
30 years old and could be theoretically classified as type
I diabetes mellitus. Eighteen (56%) recipients became
hyperglycaemic in the first 3 months after transplantation
(mean 42.6 + 20.5 days post-transplant). The remaining
14 patients developed diabetes mellitus from day 300 up
to 13 years after transplantation. The duration of diabetes
varied from 1 month to 13 years and 24 of 32 recipients
had post-transplant diabetes mellitus for more than 1
year.
Table 1. Matching criteria of patients with post-transplant diabetes
mellitus (PTDM) and controls
Matching criteria PTDM Controls
Age at transplantation (years)
(Age range)
Sex (male:female)
1st :2nd :3rd :4th graft
Serum creatinine at onset of
PTDM (umol/1)
CT:TT
45.1 + 12.61
(22-65)
22:10
27:3:1:1
141.3± 123.21
24:8
45.5+11.81
(22-62)
21:11
28:3:0:1
137.0169.21
24:8
observed in 13 (42%) diabetics and five controls
(P< 0.025). Four patients with post-transplant diabetes
mellitus suffered from chronic pancreatitis, with pancreas
surgery in their history. In three of four cases exocrine
organ insufficiency was diagnosed by reduced chymotryp-
sin excretion in the stool. One control experienced acute
pancreatitis. HLA-B8 was significantly more frequent in
diabetic patients than in controls (9 of 29 vs 2 of 31;
P<0.02) whereas HLA-A28 was only present in 2 of 29
diabetic recipients compared to 4 of 31 controls (Table 4.)
Table 3. Preoperative variables in patients with post-transplant diabetes
mellitus (PTDM) and controls
No. positive/No, tested
PTDM
(» = 32)
Controls
(" = 32)
Diabetes in family
Bodyweight (kg) at
transplantation
Impaired glucose tolerance
pretransplant (GTT)3
Pancreatitis pretransplant
4/27
59.9± 12.0'
13/312
4/32
3/24
57.94+10.01
5/31
1/32
'Mean + SD; CT, conventional therapy; TT, triple therapy
'Mean + SD
2P < 0.025 vs controls
3GTT was performed in 21 diabetics and 23 controls. In the remaining
patients impaired glucose tolerance was diagnosed by fasting blood
glucose values except in one diabetic and one control
Table 4. Diabetes-associated HLA antigens in patients with post-
transplant diabetes mellitus (PTDM) and controls
Table 2. Frequency of post-transplant diabetes mellitus in renal
transplant recipients according to immunosuppression
Insulin therapy
Oral antidiabetic
drugs
Total
TT
(CsA, Aza, Pred)
« = 273
CT
(Aza, Pred)
« = 628
3
8 (2.9%)
15
9
24 (3.8%)
TT, triple therapy; CT, conventional therapy
Total
n = 901
20
12
32 (3.6%)
HLA antigens No. positive/No, tested
PTDM
(« = 32)
Negative association with diabetes mellitus
HLA-B7 5/29
DR2 3/16
1
 P< 0.02 vs controls
Controls
(" = 32)
Positive association with diabetes mellitus
HLA-A28 2/29
B8 9/29'
B15 5/29
DR3 2/16
DR4 7/16
4/31
2/31
3/31
3/20
2/20
8/31
6/20
To evaluate predisposing factors several clinical vari-
ables were analysed both in patients with post-transplant
diabetes mellitus and in controls (Table 3). In both
groups, familial history of diabetes and bodyweight at
transplantation were similar. Impaired glucose tolerance
as measured by GTT and/or several consecutive fasting
blood glucose values prior to transplantation were
At the time of diagnosis the mean fasting blood glucose
value of the study group was 15.9 + 7.7 mmol/1 compared
to 5.2 +1.2mmol/1 in controls (P<0.00\). There was a
correlation between anti-rejection therapy with pulse
prednisone and the onset of post-transplant diabetes mel-
litus. Twelve of thirty-two (38%) patients of the study
group became diabetic during or immediately after pulse
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Table 5. Immunosuppressive therapy of diabetics and controls at onset of post-transplant diabetes mellitus
(PTDM)1
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Aza (mg/day)
Pred (mg/day)
Total dose of Pred (g)2
CsA (mg/day)
CsA blood level (ng/ml)
PTDM
CT(n = 24)
144.9 + 49.2
26.5 ±17.0
14.6+14.4
TT(n = 8)
55.4 + 22.4
27.5 + 11.6
8.4 + 9.1
282.5 + 87.8
341.7 + 195.3
Controls
CT(n = 24)
129.7 + 47.0
21.8+14.9
17.7+15.2
TT(/i = 8)
64.3 + 24.4
27.1+9.5
8.0 + 4.6
360.0+152.3
355.3 + 200.0
1
 Drug doses are expressed as mean values + SD; Cumulative dose from transplantation to onset of PTDM.
Aza, azathioprine; Pred, prednisone; CT, conventional therapy; TT, triple therapy
prednisone therapy. However, the frequency of rejection
episodes from transplantation to onset of diabetes was
similar in both groups. Eighteen of thirty-two patients
with diabetes experienced 25 rejection episodes and 21 of
32 controls had 28 rejection episodes. The basic immuno-
suppression at onset of post-transplant diabetes mellitus
is compared in Table 5. In both groups the doses of
prednisone (daily and cumulative from transplantation to
onset of post-transplant diabetes mellitus, azathioprine
and CsA were similar. Elevated CsA blood values were
observed in two patients with post-transplant diabetes
mellitus (605 and 640 ng/ml) and in one control
(736 ng/ml).
Patients with a late onset of post-transplant diabetes
mellitus (300 days to 13 years, n= 14) differed in some
aspects from patients who developed diabetes mellitus
early after transplant (42.6 + 20.5 days, «=18): only 3
of 14 'late' diabetic patients had an impaired glucose toler-
ance pretransplant as measured by GTT and/or several
consecutive fasting blood glucose levels compared to 10 of
18 patients with 'early' post-transplant diabetes mellitus
(P=n.s.). The onset of diabetes mellitus was not clearly
associated with pulse prednisone therapy (2 of 14 'late'
diabetics and 10 of 18 or 56% 'early' diabetics developed
post-transplant diabetes mellitus during or immediately
after anti-rejection therapy with pulse prednisone;
P < 0.02). Moreover, HLA-B8 was present in 1 of 12 'late'
diabetics compared to 8 of 17 patients with 'early' post-
transplant diabetes mellitus (/><0.05). Three of four
patients with chronic pancreatitis pretransplant had a late
onset of post-transplant diabetes mellitus.
During follow-up, 12 (38%) diabetic patients and six
(19%) controls had to be hospitalised because of serious
infections. The most common causes for hospitalisation
were CMV infection (« = 4), erysipelas (« = 3) and
abscesses (w = 3). Other reasons were sepsis, meningitis,
pneumonia, and urinary tract infections. Cardiovascular
complications such as myocardial infarction (w = 2), cor-
onary heart disease (n = 5) or arteriosclerosis obliterans
(« = 6) occurred in 9 of 32 patients with post-transplant
diabetes mellitus and in 3 of 32 controls (P = n.s.). Patient
and graft survival did not differ between the two groups 1,
2 and 5 years post-transplant. However, long-term graft
and patient survival were better for controls than for
diabetic patients though not significantly. At 10 years,
patient survival was 93% in controls (« at risk, 11) and
51% in diabetic patients (« at risk, 7) and graft survival
was 85% in controls (« at risk, 11) compared to 54%
in patients with post-transplant diabetes mellitus (n at
risk, 8). Eleven diabetics and three controls died during
follow-up; the main causes of death in patients with
post-transplant diabetes mellitus were cardiovascular
problems such as stroke (« = 2), myocardial infarction
(n=l) pulmonary thromboembolism (n=l) or cardio-
pulmonary failure (« = 3). Other reasons were sepsis
(« = 2), liver carcinoma («=1), and gastrointestinal
bleeding («=1). The causes of death in controls were
uraemia (patient refused dialysis), renal pelvis carcinoma,
and cardiopulmonary failure.
Discussion
Post-transplant diabetes mellitus has been described in
3%-16% of renal allograft recipients [3-11] and one
author [2] even reported occurrence in 67 of 145 patients.
Most of the literature included patients with transient
hyperglycaemia and/or without antidiabetic therapy;
therefore, the incidence of post-transplant diabetes
mellitus was higher than in the present series. Compared
to the prevalence of diabetes mellitus of 1 %-2% in a
normal population [15], post-transplant diabetes mellitus
requiring drug therapy was not a frequent complication
in our patients. Nevertheless, Gunnarsson et al [2] and
Yoshimura et al [10] noticed a high frequency of insulin-
dependent diabetes mellitus of 18% and 14% respect-
ively. In both reports greater doses of steroids than in the
present study were administered during the first months
post-transplant. The lowest incidence of 3% was
observed by McGeown et al [4], who administered
a low-dose steroid regimen (20 mg/day prednisone)
early post-transplant. Since CsA has been introduced
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in the immunosuppressive protocols following kidney
transplantation, Gunnarsson et al [16] have noted a
deterioration in the glucose metabolism of combined
kidney and pancreas allograft recipients who had
azathioprine replaced by CsA. This diabetogenic effect of
CsA is thought to be dose-dependent and reversible [17].
Subsequently, two Japanese groups [9,10] have reported a
higher frequency of post-transplant diabetes mellitus in
kidney allograft recipients treated with CsA and predni-
sone compared to conventional therapy and azathioprine
and prednisone (17% vs 13% and 8% vs 5%). This was
recently confirmed by Roth et al [11].
In our series, a higher frequency of post-transplant
diabetes mellitus in patients treated with CsA as part of
triple therapy compared to conventional therapy could
not be observed. This may be due to the fact that patients
with triple therapy were treated with smaller doses of CsA
than in the studies cited above, especially early post-
transplant. On the other hand, patients receiving triple
therapy were compared to conventionally treated patients
transplanted before 1984. Therefore, the follow-up of
the conventional therapy group was longer and it might
be possible that some patients with triple therapy will
develop post-transplant diabetes mellitus later.
To answer the question why some recipients develop
diabetes during immunosuppressive therapy while others
do not, possible predisposing and triggering factors were
examined in the literature. Gunnarsson et al [2] noted a
significant correlation between the development of post-
transplant diabetes mellitus and the total dose of predni-
sone administered or the frequency of rejection episodes.
The work of others [3,5-7] has not confirmed these
findings. In spite of the similar frequency of rejection
episodes in the study and the control group we found a
clear correlation between anti-rejection therapy with
steroid pulses and the manifestation of post-transplant
diabetes mellitus in 38% of the diabetic patients, sug-
gesting that prednisone pulses are a triggering factor in
otherwise predisposed patients.
David et al [3] proposed a genetic predisposition,
reporting a significant correlation between the presence
of HLA-A28 and the occurrence of post-transplant dia-
betes mellitus. No connections between HLA antigens
described as associated positively (HLA-B8, B15, DR3,
DR4) or negatively (HLA-B7, DR2) with insulin-
dependent diabetes [12,13] and post-transplant diabetes
mellitus have been reported in the literature. In our series,
HLA-B8 was significantly more frequent in diabetic
patients than in controls although only three patients
might be classified as having type I diabetes mellitus. The
association of HLA-B8 and insulin-dependent diabetes
mellitus has been shown to be secondary to an increase
of HLA-DR3, and was explained by the known linkage
disequilibrium between HLA-A, B, C and DR loci [18].
HLA-DR3 was not more frequent in diabetic patients
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compared to the controls. Testing for distribution of
HLA antigens in a relatively small population may turn
out to be significant merely by chance, and therefore
the presence of HLA-B8 in patients with post-transplant
diabetes mellitus cannot be clearly interpreted as a genetic
risk factor.
In some previous reports the occurrence of post-
transplant diabetes mellitus was related to familial history
of diabetes, older age or greater body weight at transplan-
tation [2,7,8,11]. In the present study, the patients were
matched according to age and therefore the hypothesis of
older age as a risk factor could not be evaluated. There
was no significant difference in bodyweight between
diabetic patients and controls. An impaired glucose toler-
ance pretransplant, as observed in almost 50% of our
diabetics, could be a risk factor for the development of
diabetes mellitus. However, Yoshimura et al [10] noted
an abnormal GTT prior to transplantation in only 18%.
Chronic pancreatitis, as observed in four patients, might
be a pathogenic factor depending on the degree of organ
dysfunction.
In the present study, patients with late onset of post-
transplant diabetes mellitus were included to evaluate
whether they showed different clinical characteristics
compared to the 'early' diabetics. Interestingly, only three
of the 'late' diabetics were predisposed by an impaired
glucose tolerance pretransplant as compared to 10 of 18
'early' diabetics. HLA-B8 was significantly more frequent
in the latter group. The finding that only two 'late'
diabetics developed post-transplant diabetes mellitus in
association with pulse prednisone may be due to the fact
that acute rejection episodes are more frequent in the early
post-transplant period. It is possible that some patients
with late onset of hyperglycaemia develop type II diabetes
independently of immunosuppression with a similar fre-
quency (14 of 901, 1.6%) as the normal population [15].
Three of four patients with chronic pancreatitis pre-
transplant were 'late' diabetics, suggesting that in these
patients the aggravation of pancreatitis rather than
immunosuppression represents a pathogenic factor.
The influence of post-transplant diabetes mellitus on
the long-term course of renal allograft recipients is not
well known. Boudreaux et al [7] reported that such
patients experienced significantly more infections requir-
ing hospitalisation than did non-diabetic recipients. A
similar trend was seen in the present series. Moreover,
a tendency to cardiovascular complications could be
observed in the patients with post-transplant diabetes
mellitus. Ten-year graft and patient survival rates were
lower in our study group than in controls, though not
significantly. Gunnarsson et al [19] and Friedman et al [6]
reported significantly poorer patient survival in diabetics
than in controls at 1 (58% vs 87% and 73% vs 83%
respectively) and 2 years (44% vs 77% and 67% vs 83%
respectively). Infections were a frequent cause of death in
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the series of Friedman, as were cardiovascular reasons in
our patients. Recently Roth et al [11] noted that actuarial
graft survival was significantly less in patients with
post-transplant diabetes mellitus at 3 and 4 years post-
transplant. David et al [3] could not establish an
unfavourable effect on either patient or transplant
outcome.
In summary, persistent post-transplant diabetes
mellitus requiring drug therapy was not a frequent
complication in our series. An abnormal GTT prior to
transplantation may identify predisposed patients. Pulse
prednisone seems to be a triggering factor, especially
in renal allograft recipients with an early onset of post-
transplant diabetes mellitus.
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